human
paramyxovirus
etiolog
agent
lifethreaten
respiratori
viru
infect
infant
young
children
virus
includ
respiratori
syncyti
viru
rsv
human
parainfluenza
virus
human
metapneumoviru
hmpv
respons
million
seriou
lower
respiratori
tract
infect
year
worldwid
current
standard
treatment
licens
vaccin
pathogen
review
research
sendai
viru
mous
parainfluenza
viru
type
advanc
jennerian
vaccin
backbon
rsv
hmpv
hpiv
vaccin
children
famili
paramyxovirida
consist
two
subfamili
paramyxovirina
pneumovirina
multipl
genera
phylogenet
tree
shown
figur
illustr
relationship
repres
virus
two
subfamili
import
human
pathogen
paramyxovirina
subfamili
includ
measl
viru
mev
mump
viru
nipah
viru
niv
hendra
viru
hev
human
parainfluenza
virus
hpiv
pneumovirina
subfamili
includ
human
respiratori
syncyti
virus
b
hrsva
hrsvb
recent
discov
human
metapneumoviru
hmpv
structur
paramyxoviru
illustr
figur
envelop
virus
encas
lipid
bilay
deriv
plasma
membran
host
cell
contain
singlestrand
nonseg
neg
strand
rna
genom
approxim
kb
paramyxovirus
best
known
etiolog
agent
seriou
pediatr
respiratori
tract
diseas
rsv
hpiv
hmpv
rsv
major
caus
seriou
pediatr
hospit
throughout
world
due
acut
lower
respiratori
tract
infect
alri
year
age
almost
children
expos
rsv
viru
caus
lifethreaten
bronchiol
pneumonia
unit
state
alon
infant
age
month
hospit
year
due
rsv
infect
cost
sever
hundr
million
dollar
worldwid
approxim
million
episod
rsvassoci
alri
children
less
year
age
least
million
case
result
hospit
comprehens
review
rsv
incid
among
infant
across
sever
countri
reveal
rang
case
rsvassoci
sever
alri
per
children
year
age
group
worldwid
may
death
per
year
occur
develop
countri
infant
highli
vulner
rsv
upon
first
exposur
particularli
prematur
immunodefici
suffer
congenit
heart
lung
diseas
matern
antibodi
protect
neonat
antibodi
titer
correl
improv
outcom
antibodi
wane
rapidli
first
month
life
survivor
first
infect
endogen
protect
immun
respons
usual
gener
diseas
caus
second
exposur
viru
often
mild
hospit
rel
rare
nonetheless
first
episod
diseas
follow
longterm
sequela
includ
wheez
asthma
current
vaccin
standard
treatment
vulner
palivizumab
monoclon
antibodi
treatment
recommend
prevent
rsv
ill
costli
form
prophylaxi
unavail
individu
need
furthermor
signific
fraction
children
progress
seriou
diseas
despit
palivizumab
treatment
new
antibodi
develop
recent
year
replac
palivizumab
motavizumab
improv
efficaci
insuffici
support
advanc
drug
develop
human
parainfluenza
virus
exist
four
distinct
serotyp
type
caus
diseas
one
studi
respect
respons
percent
pediatr
hospit
respiratori
diseas
identifi
rare
caus
diseas
although
children
like
infect
evidenc
seropreval
data
group
parainfluenza
virus
may
caus
mani
alri
rsv
consequ
usual
sever
hpiv
type
respons
case
laryngotracheobronch
better
known
croup
also
caus
bronchiol
tracheobronch
pneumonia
wheez
form
lower
respiratori
tract
diseas
viral
diseas
usual
strike
children
age
greater
month
outbreak
may
occur
biennial
sometim
altern
year
one
anoth
children
recov
viru
infect
develop
world
signific
morbid
experienc
also
consider
financi
burden
miss
work
caregiv
virus
deadli
patient
suffer
immunodefici
one
unit
state
studi
conduct
among
children
year
age
septemb
decemb
epidem
year
monitor
infect
result
extrapol
suggest
approxim
emerg
room
visit
hospit
year
nation
caus
overal
cost
approach
million
us
dollar
differ
often
strike
children
less
month
age
second
rsv
caus
bronchiol
pneumonia
young
infant
hmpv
discov
sinc
center
diseas
control
prevent
cdc
collect
data
children
suffer
alri
result
show
among
infant
less
month
age
hmpv
respons
annual
rate
hospit
approxim
per
similar
studi
soweto
reveal
rate
approxim
per
infant
year
hospit
rate
less
report
rsv
combin
hpiv
clearli
indic
signific
morbid
pediatr
diseas
caus
hmpv
includ
pneumonia
bronchiol
asthma
young
infant
children
clearli
constitut
highli
vulner
popul
paramyxovirus
victim
elderli
adult
peopl
age
compromis
immun
pulmonari
cardiac
system
highli
suscept
rsv
hmpv
hpiv
exampl
may
elderli
person
die
annual
unit
state
alon
diseas
relat
rsv
infect
solut
includ
licens
antivir
prevent
vaccin
yet
avail
age
group
base
epidemiolog
impact
paramyxovirus
current
vaccin
program
target
multipl
popul
includ
immunolog
infant
less
month
age
rsv
elderli
addit
current
focu
young
schoolag
children
children
often
infect
although
serious
ill
may
frequent
transmit
rsv
highrisk
popul
vaccin
program
also
current
target
women
childbear
year
expect
mother
boost
matern
antibodi
level
vaccin
may
reduc
infect
diseas
mother
infant
upon
passiv
transfer
hightit
antibodi
birth
plethora
approach
taken
develop
vaccin
rsv
hmpv
hpiv
review
inactiv
wholeviru
vaccin
trial
use
formalininactiv
rsv
firsv
trival
cocktail
fihpiv
includ
type
fail
protect
children
infect
notori
case
firsv
vaccin
enhanc
ill
vaccin
individu
natur
expos
rsv
unexpect
outcom
develop
wholeinactiv
vaccin
infant
sinc
discourag
rsv
field
purifi
protein
vaccin
pursu
decad
much
attent
given
g
f
protein
rsv
today
rsv
f
protein
use
preferenti
rsv
vaccin
candid
due
high
conserv
among
circul
viral
isol
mani
protein
extern
intern
use
eg
g
sh
np
p
proteinbas
vaccin
candid
includ
subunit
purifi
protein
peptid
particul
viruslik
particl
virosom
nanoparticl
prepar
rsv
f
protein
present
postfus
prefus
conform
shown
merit
number
neutral
monoclon
antibodi
bind
site
map
precis
one
two
form
nanoparticl
vaccin
produc
postfus
f
protein
deriv
baculoviru
advanc
clinic
trial
elderli
women
childbear
age
encourag
result
anoth
strategi
paramyxoviru
vaccin
develop
util
nonvir
genebas
vector
includ
rna
dna
latter
deliv
purifi
form
bacteriamedi
plasmid
transfer
current
purifi
protein
vaccin
vaccin
replic
incompet
describ
deem
attract
elderli
popul
replicationcompet
mucos
vaccin
deem
attract
young
infant
possibl
prefer
chang
time
new
vaccin
develop
date
preclin
clinic
test
conduct
use
numer
replicationcompet
vaccin
includ
attenu
eg
coldadapt
sitedirect
mutagenesi
rsv
hpiv
chimer
vaccin
replicationcompet
vaccin
backbon
use
deliv
rsv
hpiv
andor
hmpv
antigen
includ
poxviru
alphaviru
adenoviru
adenoassoci
viru
aav
measl
viru
bovin
newcastl
diseas
viru
ndv
sev
focu
present
review
sev
mous
parainfluenza
viru
type
discov
sendai
japan
viru
name
hemagglutin
viru
japan
hvj
japanes
societi
virolog
later
term
newborn
viru
pneumon
type
sendai
name
sendai
viru
sev
current
popular
viru
first
recov
mous
use
passag
human
patient
sampl
caus
confus
viru
origin
sev
understood
pathogen
mice
human
fukumi
et
al
first
describ
sev
infect
mice
infect
subclin
sev
also
known
one
lead
caus
pneumonia
certain
mous
strain
sev
uniqu
sensit
interferonassoci
respons
human
perhap
explain
least
part
hostrang
restrict
sev
grow
high
titer
chicken
egg
fdaapprov
mammalian
cell
line
advantag
vaccin
product
sev
member
respiroviru
genu
paramyxovirina
subfamili
paramyxovirus
sev
envelop
viru
nonseg
negativestrand
rna
genom
schemat
sev
genom
shown
top
figur
sev
genom
includ
leader
sequenc
trailer
six
structur
gene
transcrib
order
nucleocapsid
n
phosphoprotein
p
matrix
fusion
f
hemagglutininneuraminidas
hn
larg
polymeras
l
noteworthi
sever
addit
protein
produc
leaki
scan
yield
c
c
protein
pseudotempl
addit
nucleotid
otherwis
known
mrna
edit
yield
v
w
protein
core
virion
helic
nucleocapsid
contain
viral
rna
genom
n
p
l
protein
see
figur
effici
replic
sev
genom
antigenom
requir
total
number
rna
nucleotid
even
multipl
six
therefor
necessari
obey
rule
six
clone
foreign
antigen
insert
sev
vector
protein
abund
protein
virion
function
promot
virusparticl
format
interact
nucleocapsid
plasma
membran
host
cell
cytoplasm
tail
f
hn
envelop
glycoprotein
f
hn
protein
type
ii
membran
protein
respect
ectodomain
project
spike
perpendicularli
surfac
viral
envelop
viru
entri
hn
protein
bind
sialicacid
contain
receptor
plasma
membran
surfac
trigger
f
protein
neutral
ph
refold
hairpin
structur
caus
fusion
viral
host
cell
membran
envelop
glycoprotein
traffick
cell
surfac
hn
protein
destroy
receptor
allow
effici
releas
progeni
virion
prevent
virion
aggregr
superinfect
previous
infect
cell
polar
mechan
sev
transcript
typic
paramyxovirus
member
order
mononegaviral
negativestrand
rna
virus
gene
tandem
singl
genom
see
figur
top
diagram
sev
n
gene
transcrib
first
initi
n
mrna
transcript
complet
gene
viral
gene
junction
contain
gene
end
region
intergen
region
guu
russel
gene
start
sequenc
gene
junction
viral
rnadepend
rna
polymeras
rdrp
direct
termin
transcript
polyadenyl
nascent
mrna
reiniti
transcript
next
gene
howev
frequenc
reiniti
transcript
imprecis
depend
ident
transcript
start
sequenc
result
gradient
mrna
transcript
produc
follow
abund
n
p
f
hn
l
consequ
foreign
report
gene
vaccin
antigen
insert
sev
genom
degre
insert
posit
toward
initi
end
genom
determin
extent
foreign
gene
express
degre
sev
replic
attenu
sev
mous
parainfluenza
viru
type
advanc
jennerian
vaccin
strategi
follow
edward
jenner
clinician
late
test
substanc
cow
lesion
vaccin
human
smallpox
viru
unbeknownst
jenner
time
substanc
cowpox
viru
share
signific
protein
similar
smallpox
viru
therefor
prime
crossreact
lymphocyt
includ
b
cell
helper
h
cell
cytotox
lymphocyt
ctl
furthermor
livevir
vaccin
could
elicit
immun
respons
last
decad
singl
immun
jenner
vaccin
strategi
eventu
advanc
around
globe
campaign
sponsor
world
health
organ
result
complet
erad
smallpox
human
popul
vaccin
yet
match
degre
success
research
st
jude
observ
sev
like
cowpox
smallpox
well
match
protein
sequenc
result
encourag
test
b
cell
h
cell
ctl
crossreact
two
virus
inde
signific
crossreact
cellular
humor
activ
test
mice
sev
could
elicit
rapid
durabl
pivspecif
b
cell
cell
respons
system
also
respiratori
mucosa
respons
gener
peak
within
first
month
postvaccin
sustain
signific
valu
sera
respiratori
tissu
anim
lifetim
due
longlast
virusspecif
cell
respiratori
tract
anim
maintain
robust
defens
pathogen
point
entri
potenti
sev
jennerian
vaccin
reveal
mice
vaccin
subsequ
challeng
sev
adult
young
mice
protect
experi
african
green
monkey
conduct
support
translat
sev
vaccin
human
clinic
trial
monkey
vaccin
boost
sev
intranas
vaccin
infect
respiratori
tract
transient
clear
evid
advers
event
serum
antibodi
respons
identifi
day
first
vaccin
monkey
also
exhibit
serum
neutral
activ
antibodi
measur
blood
nasal
passag
vaccin
monkey
challeng
anim
complet
protect
infect
wherea
control
anim
infect
preclin
result
encourag
advanc
sev
clinic
studi
vaccin
fda
oversight
sev
test
first
adult
year
old
children
seroposit
age
group
three
sequenti
dose
sev
test
eid
vaccin
well
toler
particip
boost
preexist
pivspecif
bind
neutral
antibodi
activ
observ
subset
adult
major
children
suggest
even
individu
alreadi
seroposit
hesh
may
benefit
vaccin
sev
clinic
studi
sev
year
old
children
current
underway
sev
particularli
attract
human
vaccin
known
pathogen
mice
never
caus
confirm
diseas
human
sev
attenu
human
viru
therefor
burden
concern
revert
origin
pathogen
phenotyp
sev
also
attract
grow
transient
mammalian
cell
allow
cell
express
antigen
endogen
posttransl
modif
match
target
antigen
neutral
epitop
endogen
express
antigen
also
ensur
robust
activ
cell
cell
provid
failsaf
mechan
antibodi
complet
elimin
incom
infecti
particl
cell
kill
infect
mammalian
cell
block
viru
amplif
advent
revers
genet
possibl
use
sev
backbon
rsv
vaccin
realiz
sev
accommod
foreign
gene
gene
larg
size
specif
demonstr
sakai
et
al
gene
kb
insert
effici
express
sev
sev
vector
produc
either
rsv
f
g
gene
insert
f
hn
gene
sev
figur
depict
insert
rsv
f
f
hn
gene
sev
genom
follow
vaccin
sev
deliv
rsv
f
gene
mammalian
cell
rsv
f
gene
transcrib
rdrp
cytoplasm
translat
endoplasm
reticulum
traffick
secretori
pathway
surfac
mammalian
host
cell
rsv
protein
like
mammalian
protein
exclud
progeni
sev
virion
viru
assembl
bud
origin
propos
least
two
vector
may
requir
repres
rsv
subtyp
b
howev
singl
sev
vector
express
fulllength
rsv
f
protein
secret
f
protein
ectodomain
prove
suffici
gener
neutral
antibodi
protect
cotton
rat
varieti
rsv
challeng
includ
primari
isol
b
subtyp
result
consist
find
palivizumab
monoclon
antibodi
rsv
f
provid
signific
prophylaxi
strain
rsv
enhanc
immunopatholog
vaccin
anim
upon
rsv
challeng
unlik
situat
previous
experienc
illfat
firsv
vaccin
cotton
rat
model
vaccin
also
efficaci
administ
presenc
matern
antibodi
titer
typic
month
old
human
infant
recombin
sev
express
fulllength
rsv
f
protein
strain
test
african
green
monkey
per
fda
request
vaccin
administ
intranas
intratrach
transient
vaccin
infect
observ
advers
event
upon
intranas
challeng
test
control
anim
rsv
vaccin
anim
control
complet
protect
rsv
infect
lower
respiratori
tract
sevrsvf
recombin
manufactur
clinic
test
meanwhil
anoth
recombin
sevbas
vaccin
advanc
clinic
studi
vaccin
develop
intern
aid
vaccin
initi
dnavec
corpor
prevent
hiv
clinic
protocol
involv
primeboost
adult
particip
use
recombin
sev
express
gag
adenoviru
vector
express
fusion
protein
compris
gag
revers
transcriptas
integras
nef
grin
studi
initi
rwanda
kenya
unit
kingdom
first
result
suggest
safeti
induct
cellular
humor
immun
respons
studi
particip
follow
success
sevbas
rsv
vaccin
preclin
studi
number
addit
recombin
produc
specif
hemagglutinin
protein
individu
insert
sev
backbon
new
vaccin
shown
protect
cotton
rat
challeng
target
pathogen
protect
sevbas
hmpv
vaccin
also
success
test
cotton
rat
model
unpublish
data
addit
shown
sev
vaccin
could
mix
togeth
singl
intranas
applic
exampl
three
sev
recombin
mix
cocktail
simultan
vaccin
cotton
rat
vaccin
compon
express
hn
protein
hn
protein
rsv
f
protein
respect
upon
challeng
either
rsv
vaccin
anim
protect
challeng
virus
result
demonstr
strength
sev
cocktail
vaccin
approach
mean
target
sever
paramyxoviru
pathogen
singl
sev
vector
may
also
accommod
one
gene
two
gene
repres
differ
pathogen
might
insert
tandem
differ
posit
within
sev
backbon
strategi
current
investig
sev
also
use
combin
vaccin
platform
either
administ
time
primeboost
protocol
tabl
centuri
ago
number
measl
case
singl
year
unit
state
reach
year
measl
declar
elimin
unit
state
today
comparison
past
year
case
drop
outbreak
occur
due
import
measl
viru
travel
exposur
unvaccin
popul
similarli
mump
viru
infect
reduc
unit
state
modern
vaccin
era
compar
prevaccin
era
mmr
vaccin
success
illustr
attribut
live
viral
vaccin
durabl
humor
cellular
immun
respons
induc
function
interact
antibodi
bind
neutral
viru
particl
first
line
defens
cell
secret
cytokin
kill
virusinfect
cell
ifwhen
antibodi
steril
possibl
sev
one
day
serv
anoth
success
live
viral
vaccin
prevent
paramyxovirus
infect
sev
vector
mani
attract
qualiti
outlin
review
tabl
basic
research
laboratori
continu
introduc
new
strategi
eg
insert
one
foreign
gene
singl
sev
backbon
new
vaccin
combin
new
pathogen
target
perhap
clinic
studi
conduct
next
year
culmin
proof
efficaci
human
licensur
sevbas
vaccin
product
protect
human
respiratori
viru
infect
respiratori
paramyxovirus
kill
hundr
thousand
individu
year
hospit
million
standard
treatment
licens
vaccin
virus
sendai
viru
sev
base
vaccin
safe
protect
paramyxoviru
infect
small
larg
research
anim
phase
clinic
studi
demonstr
sev
safeti
immunogen
adult
children
russel
genom
shown
includ
sendai
viru
sev
blue
respiratori
syncyti
viru
rsv
green
sevvector
vaccin
rsv
f
protein
insert
sev
f
hn
gene
sevrsv
genom
leader
posit
left
terminu
trailer
right
intergen
junction
gene
shown
contain
transcript
stop
intergen
transcript
start
sequenc
sev
p
gene
leaki
scan
product
includ
c
c
protein
brown
also
sev
p
gene
mrna
edit
produc
v
w
protein
share
ntermin
portion
v
blue
altern
read
frame
ctermin
portion
orang
simplic
altern
product
p
gene
omit
sevrsv
schemat
rsv
genom
gene
contain
two
overlap
product
rsv
l
gene
also
overlap
genom
drawn
scale
bottom
russel
expert
rev
vaccin
author
manuscript
avail
pmc
januari
